Tumors exhibit a vast array of genetic alterations that drive their initiation, growth, and progression. These mutations can confer selective advantages to cancer cells, leading to immune evasion and therapy resistance. Additionally, the tumor microenvironment plays a crucial role in shaping the interactions between tumor cells and the immune system, influencing treatment outcomes.
Understanding how specific tumor mutations contribute to immune evasion is essential for developing effective immunotherapies. Certain oncogenic mutations can result in the production of neoantigens, which can elicit an immune response. However, tumor cells have evolved numerous mechanisms to evade immune surveillance, including downregulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and recruitment of immunosuppressive cells. Investigating the interplay between tumor mutations and immune evasion mechanisms will shed light on the molecular basis of treatment resistance and help identify potential targets for intervention.
Targeted therapies have revolutionized cancer treatment by selectively inhibiting key signaling pathways driving tumor growth. However, the emergence of resistance remains a major challenge. Recent studies have shown that immune evasion mechanisms, such as upregulation of immune checkpoints or alterations in antigen presentation machinery, can confer resistance to targeted therapies. Investigating the crosstalk between immune evasion and targeted therapy resistance will provide insights into the complex adaptive responses of tumor cells, paving the way for the development of combination strategies that simultaneously target both pathways.
This Research Topic will explore cutting-edge research aimed at developing innovative therapeutic approaches that exploit the interplay between tumor mutations, immune evasion, and targeted therapy resistance. We welcome Original Research, Mini Reviews, Perspectives, Brief Research Reports and Methods that cover, but are not limited to, the following:
1. Exploring the impact of tumor mutational processes on immune recognition and response.
2. Overcoming therapy resistance driven by clonal evolution and tumor heterogeneity.
3. Therapeutic modulation of the tumor immune microenvironment to enhance immunotherapy efficacy.
4. Investigating the role of noncoding mutations in cancer progression and therapeutic response.
5. Development of combination therapies targeting mutational drivers and the tumor microenvironment.
6. Immunogenomic profiling of tumors to identify therapeutic vulnerabilities.
7. Investigating the impact of chromosomal instability on tumor evolution and response to treatment.
8. The role of tumor-associated neoantigens in shaping the immune response and guiding cancer therapy.
9. The impact of metabolic alterations in tumor cells and the microenvironment on therapeutic strategies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Dr. Shanye Yin is a shareholder of Yihui Bio, INC. The other editors declare no conflict of interests.
Tumors exhibit a vast array of genetic alterations that drive their initiation, growth, and progression. These mutations can confer selective advantages to cancer cells, leading to immune evasion and therapy resistance. Additionally, the tumor microenvironment plays a crucial role in shaping the interactions between tumor cells and the immune system, influencing treatment outcomes.
Understanding how specific tumor mutations contribute to immune evasion is essential for developing effective immunotherapies. Certain oncogenic mutations can result in the production of neoantigens, which can elicit an immune response. However, tumor cells have evolved numerous mechanisms to evade immune surveillance, including downregulation of antigen presentation machinery, upregulation of immune checkpoint molecules, and recruitment of immunosuppressive cells. Investigating the interplay between tumor mutations and immune evasion mechanisms will shed light on the molecular basis of treatment resistance and help identify potential targets for intervention.
Targeted therapies have revolutionized cancer treatment by selectively inhibiting key signaling pathways driving tumor growth. However, the emergence of resistance remains a major challenge. Recent studies have shown that immune evasion mechanisms, such as upregulation of immune checkpoints or alterations in antigen presentation machinery, can confer resistance to targeted therapies. Investigating the crosstalk between immune evasion and targeted therapy resistance will provide insights into the complex adaptive responses of tumor cells, paving the way for the development of combination strategies that simultaneously target both pathways.
This Research Topic will explore cutting-edge research aimed at developing innovative therapeutic approaches that exploit the interplay between tumor mutations, immune evasion, and targeted therapy resistance. We welcome Original Research, Mini Reviews, Perspectives, Brief Research Reports and Methods that cover, but are not limited to, the following:
1. Exploring the impact of tumor mutational processes on immune recognition and response.
2. Overcoming therapy resistance driven by clonal evolution and tumor heterogeneity.
3. Therapeutic modulation of the tumor immune microenvironment to enhance immunotherapy efficacy.
4. Investigating the role of noncoding mutations in cancer progression and therapeutic response.
5. Development of combination therapies targeting mutational drivers and the tumor microenvironment.
6. Immunogenomic profiling of tumors to identify therapeutic vulnerabilities.
7. Investigating the impact of chromosomal instability on tumor evolution and response to treatment.
8. The role of tumor-associated neoantigens in shaping the immune response and guiding cancer therapy.
9. The impact of metabolic alterations in tumor cells and the microenvironment on therapeutic strategies.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Dr. Shanye Yin is a shareholder of Yihui Bio, INC. The other editors declare no conflict of interests.